Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Mass spectrometry, data re-analysis, and homology modelling predict posttranslational modifications of leucine-rich alpha-2-glycoprotein as a marker of myelodysplastic syndrome

P. Majek, Z. Sovova, K. Pecankova, J. Cermak, Z. Gasova, P. Pecherkova, V. Ignjatovic, JE. Dyr

. 2022 ; 34 (3) : 485-492. [pub] -

Language English Country Netherlands

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22019498

BACKGROUND: Leucine-rich alpha-2-glycoprotein (LRG) has been repeatedly proposed as a potential plasma biomarker for myelodysplastic syndrome (MDS). OBJECTIVE: The goal of our work was to establish the total LRG plasma level and LRG posttranslational modifications (PTMs) as a suitable MDS biomarker. METHODS: The total plasma LRG concentration was determined with ELISA, whilst the LRG-specific PTMs and their locations, were established using mass spectrometry and public mass spectrometry data re-analysis. Homology modelling and sequence analysis were used to establish the potential impact of PTMs on LRG functions via their impact on the LRG structure. RESULTS: While the results showed that the total LRG plasma concentration is not a suitable MDS marker, alterations within two LRG sites correlated with MDS diagnosis (p= 0.0011). Sequence analysis and the homology model suggest the influence of PTMs within the two LRG sites on the function of this protein. CONCLUSIONS: We report the presence of LRG proteoforms that correlate with diagnosis in the plasma of MDS patients. The combination of mass spectrometry, re-analysis of publicly available data, and homology modelling, represents an approach that can be used for any protein to predict clinically relevant protein sites for biomarker research despite the character of the PTMs being unknown.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019498
003      
CZ-PrNML
005      
20231102132612.0
007      
ta
008      
220720s2022 ne f 000 0|eng||
009      
AR
024    7_
$a 10.3233/CBM-210033 $2 doi
035    __
$a (PubMed)35275518
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Majek, Pavel $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
245    10
$a Mass spectrometry, data re-analysis, and homology modelling predict posttranslational modifications of leucine-rich alpha-2-glycoprotein as a marker of myelodysplastic syndrome / $c P. Majek, Z. Sovova, K. Pecankova, J. Cermak, Z. Gasova, P. Pecherkova, V. Ignjatovic, JE. Dyr
520    9_
$a BACKGROUND: Leucine-rich alpha-2-glycoprotein (LRG) has been repeatedly proposed as a potential plasma biomarker for myelodysplastic syndrome (MDS). OBJECTIVE: The goal of our work was to establish the total LRG plasma level and LRG posttranslational modifications (PTMs) as a suitable MDS biomarker. METHODS: The total plasma LRG concentration was determined with ELISA, whilst the LRG-specific PTMs and their locations, were established using mass spectrometry and public mass spectrometry data re-analysis. Homology modelling and sequence analysis were used to establish the potential impact of PTMs on LRG functions via their impact on the LRG structure. RESULTS: While the results showed that the total LRG plasma concentration is not a suitable MDS marker, alterations within two LRG sites correlated with MDS diagnosis (p= 0.0011). Sequence analysis and the homology model suggest the influence of PTMs within the two LRG sites on the function of this protein. CONCLUSIONS: We report the presence of LRG proteoforms that correlate with diagnosis in the plasma of MDS patients. The combination of mass spectrometry, re-analysis of publicly available data, and homology modelling, represents an approach that can be used for any protein to predict clinically relevant protein sites for biomarker research despite the character of the PTMs being unknown.
650    _2
$a biologické markery $7 D015415
650    12
$a glykoproteiny $x genetika $x metabolismus $7 D006023
650    _2
$a lidé $7 D006801
650    _2
$a leucin $x metabolismus $7 D007930
650    _2
$a hmotnostní spektrometrie $7 D013058
650    12
$a myelodysplastické syndromy $x diagnóza $7 D009190
650    _2
$a posttranslační úpravy proteinů $7 D011499
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sovova, Zofie $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Pecankova, Klara $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Cermak, Jaroslav $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Gasova, Zdenka $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Pecherková, Pavla, $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $d 1980- $7 ctu2013787641
700    1_
$a Ignjatovic, Vera $u Murdoch Children's Research Institute, Parkville Victoria, Australia $u Department of Paediatrics, The University of Melbourne, Parkville Victoria, Australia
700    1_
$a Dyr, Jan E $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
773    0_
$w MED00173146 $t Disease markers. Section A, Cancer Biomarkers $x 1875-8592 $g Roč. 34, č. 3 (2022), s. 485-492
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35275518 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20231102132607 $b ABA008
999    __
$a ok $b bmc $g 1822902 $s 1170741
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 34 $c 3 $d 485-492 $e - $i 1875-8592 $m Disease markers. Section A, Cancer Biomarkers $n Cancer Biomark $x MED00173146
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options